Skip to Content

Adalimumab Biosimilars in Psoriasis

While biologics are expensive drugs, biosimilar drugs are way more accessible. In this MEDtalk, MD, and Ph.D. Nikolai Nguyen Loft reports exciting results from Denmark, highlighting the potential consequences of switching patients with psoriasis from the adalimumab originator to one of the two existing adalimumab biosimilar. Fortunately, the real-world data suggest efficacy and safety of adalimumab biosimilar are similar to the originator.

Nikolai Nguyen Loft

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top